Baird Medical Investment Holdings Limited logo

Baird Medical Investment Holdings Limited(BDMD)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
1-STAR RATING
PASS
LAST CLOSE
$0.09
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for BDMD

11/13/2026: BDMD (1-star) is currently NOT-A-BUY. Pass it for now.

Baird Medical Investment Holdings Limited is a specialized medical technology company that develops and sells microwave ablation devices for minimally invasive tumor treatments. The company benefits from high gross profit margins and a razor-and-blade model anchored by recurring consumable needle utilization. Its primary growth catalyst lies in international expansion, highlighted by U.S. commercial leadership appointments and regulatory filings for advanced ablation systems. However, the business faces significant headwinds, including heavy revenue dependence on Mainland China procurement trends, uncollected receivables, and recent operating losses. Investors should monitor U.S. market adoption progress and cash flow stabilization while weighing its high volatility and speculative risk profile.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitWhile international expansion initiatives offer growth potential, recent revenue contraction and execution hurdles introduce uncertainty.
Weak fitThe stock has experienced sharp downward price pressure and trades near historical lows, making it conditional on a confirmed technical upturn signal.
Value investorMixed fitHigh gross margins provide an appealing baseline, but ongoing operating losses and cash burn offset deep-value appeal.
Dividend investorWeak fitThe company does not pay dividends, directing all capital toward product innovation and global market entry.
Low-risk investorWeak fitHigh share price volatility, regulatory exposure, and financial swings present risks unsuited for conservative risk profiles.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock has shown wide trading ranges and steep downward swings, heightening near-term risk.
Valuation riskMedium / highMarket sentiment has shifted heavily, discounting the equity amidst volatile earnings execution.
Competition risk (Medtronic and multinational medical device giants)HighWell-capitalized competitors can leverage extensive distribution networks to bundle products and crowd out smaller players.
Business qualityMediumRobust product gross margins reflect solid unit economics, though constrained by volatile cash collections.
Dividend incomeLow / noneNo payouts are distributed to shareholders.
Execution riskHighSuccess depends heavily on executing the international commercial transition into Western markets smoothly.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 2.91M USD
Price to earnings Ratio -
1Y Target Price 4
Price to earnings Ratio -
1Y Target Price 4
Volume (30-day avg) 33.2M shares
Beta -0.99
52 Weeks Range 0.07 - 3.70
Updated Date 11/15/2026
52 Weeks Range 0.07 - 3.70
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -0.55

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Devices

BUY participation
62.5%
Active BUY / eligible
5 / 8
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -21.36%
Avg. Invested days 13
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 1.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
BDMD receives a 2-star rating, reflecting soft or weak scores across the available pillars. The rating is constrained by weak unit economics, soft analyst coverage, and weak price momentum.

Company Fundamentals

★★★★★
BDMD has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and moderate ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-319.0%), weak cash generation (FCF margin -6.2%), negative revenue growth (-39.2%).

Financial Health Rating

★★★★★
BDMD's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 32.4%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is BDMD's strongest growth driver at +84.9% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (-39.2%, negative) and earnings growth (-319.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 0.9% (soft) and 20.2% of outstanding shares are publicly tradable (soft). Insider ownership of 86.61% supports management-shareholder alignment.

Top 5 Institutional Investors

Renaissance Technologies Corp 0.23%
UBS Group AG 0.18%
Two Sigma Investments LLC 0.17%
Citadel Advisors Llc 0.17%
Jane Street Group LLC 0.10%

Unit Economics (Per $1K Revenue)

★★★★★
BDMD generates approximately $838 of gross profit, $-1,133 of operating income, and $-62 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -4.42% (Tax Credit)

Quantitative Style Profile

★★★★★
BDMD has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Microwave Ablation Devices and GeneratorsSale of durable capital equipment hardware to hospitals and medical centers.This serves as the initial equipment placement phase of their business model.
Microwave Ablation Needles and DisposablesConsumable needle sales utilized during repeated tumor ablation procedures.This represents the recurring razor-and-blade revenue stream tied directly to hospital procedure volumes.
Geographic Exposure (Mainland China & International)Product sales via direct channels in domestic markets and third-party distributors spanning Hong Kong, Southeast Asia, and expanding global territories.Regional policy changes heavily impact domestic results, making international diversification critical.

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Valuation

Trailing PE -
Forward PE 0.65
Enterprise Value 21.65M
Price to Sales(TTM) 0.12
Enterprise Value 21.65M
Price to Sales(TTM) 0.12
Enterprise Value to Revenue 0.88
Enterprise Value to EBITDA 5.91
Shares Outstanding 32.11M
Shares Floating 6.50M
Shares Outstanding 32.11M
Shares Floating 6.50M
Percent Insiders 86.61
Percent Institutions 0.94

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.